Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT04165096
Brief Title: KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

First Submitted : November 14, 2019
First Submitted that Met QC Criteria : November 14, 2019
First Posted : November 15, 2019

Last Update Submitted that Met QC Criteria : June 10, 2021
Last Update Posted : June 15, 2021